Author: Admin

Developer

Salem News Channel Adds Wilkow

Posted on by Admin



Salem News Channel Adds Wilkow

Research, News, and Market Data on Salem Media

 

IRVING, Texas–(BUSINESS WIRE)– Salem Media Group, Inc. (NASDAQ: SALM) announced that Salem News Channel is adding Andrew Wilkow to its weekday television lineup. The new show named “Wilkow!” will be a combination of breaking news from the day, and what to make of it from the host’s perspective. It will air weekdays from 5-6pm Eastern Time, starting Tuesday, February 15th.

Andrew Wilkow (Photo: Business Wire)

Andrew Wilkow (Photo: Business Wire)

For the last 7 years, Wilkow has hosted a regular show on The Blaze TV network. He has also hosted the show “Wilkow Majority” for the last 16 years on Sirius XM Satellite Radio, and he will continue his show there.

“I cannot wait to move ‘Wilkow!’ onto the Salem News Channel,” said Wilkow. “The 5pm hour is the starting point of the evening news cycle. Our plan is to give the viewer an hour of live TV that combines perfectly executed political analysis and whatever breaking stories are happening.”

The show will originate out of Salem’s New York City studio in Lower Manhattan and will be the first of many TV only hours being produced by SNC. “This is not going to be a clone program. Starting February 15th, we are going to bring passion and fire to the 5 pm hour every day,” added Wilkow.

Salem News Channel is a new OTT television network, available on SalemNewsChannel.com, the Apple and Android app of the same name, and on Roku Devices worldwide, and on Apple TV. “Andrew is a perfect fit for SNC and all of the hosts already there,” said Salem Senior VP of Spoken Word Formats Phil Boyce. “Andrew has carved out a name for himself on the Sirius Patriot Channel. His many followers will have a great time watching him on our new TV network.”

Salem News Channel is now home to the video simulcasts of its popular radio shows like Hugh Hewitt, Mike Gallagher, Dennis Prager, Sebastian Gorka, and Larry Elder.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.com, Facebook and Twitter.

Evan D. Masyr
Executive Vice President and Chief
Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group

Release – ProMIS Neurosciences Appoints Renowned Neuroscientists Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

Posted on by Admin



ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

News and Market Data on ProMIS Neurosciences

 

TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).

Dr. Guy Rouleau, MD, PhD, is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. Over the last two decades, Dr. Rouleau and his team have focused on identifying genes associated with neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to disease symptoms.

Dr. Alain Dagher, MD, has been an attending neurologist at the Montreal Neurological Institute since 1997. His clinical specialty is movement disorders, with a focus on Parkinson’s Disease. His main research interest is functional brain imaging to understand the function of the basal ganglia, frontal lobes and dopamine in reward-seeking behaviors. This research has shed light on the cognitive deficits in Parkinson’s disease, stress and anxiety, schizophrenia, drug addiction, obesity, and pathological gambling and other behavioral addictions.

“On behalf of the ProMIS executive team I am delighted to welcome Drs. Rouleau and Dagher to our scientific advisory board”, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “Their outstanding scientific contributions to a broad area of neurodegenerative, neurological and neuropsychiatric diseases is an excellent fit with ProMIS’s technology platform and portfolio of antibodies selectively targeting the toxic, misfolded proteins that are implicated in these devastating disorders.”

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF
Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: ProMIS Neurosciences Inc.

Verifying Cannabis COAs with NFTs

Posted on by Admin 


  Image: ACS Laboratories


Can Marijuana Businesses Benefit from NFTs?

 

Non-fungible tokens (NFT) are developing a growing role in cannabis businesses. While cryptocurrency may still be used to carry out transactions without involving a bank, NFTs are being adopted to create interest in brands and to verify they are tested and are bonafide by validating the Certificate of Authenticity (COA).

Branding

As a business, cannabis sales are like many others. First, produce a product people want, then build followers of the product. Many large popular companies have adopted the use of NFTs to build their brand and reach different consumer types. One example of this is the Under Armour Curry Flow Sneaker. In December, when brand ambassador Stephen Curry broke the NBA’s three-point record, Under Armour (NYSE: UAA) celebrated by releasing a collection of nonfungible tokens (NFTs) related to the shoe.

Gary Vaynerchuk, motivational influencer and founder of The Wine Library recently announced he will open a restaurant where patrons must purchase NFTs to gain membership.

Adidas and the Bored Ape Yacht Club have partnered to offer NFTs that allow owners exclusive access to buy real-world physical products.  Another shoe company, Nike (NYSE:NKE) bought RTFKT, which makes NFTs and shoes only used within the metaverse. In this way users who are seen at home just doing it in their Nikes can portray themselves similarly in the metaverse.

As for Cannabis companies, It’s easy to understand how the attention received by NFTs can be used to help stand out among competitors. Within the metaverse, consumers see the same brands that exist in the physical world; added recognition can make the products more desirable in both. Jeffrey Welsh, an intellectual and entertainment lawyer for Denver-based law firm Vicente Sederberg, said the “low-hanging fruit” for marijuana businesses is to build memberships around NFTs that are associated with cool or unique digital assets that, in turn, are connected to products such as popular or exotic strains.” Sederberg concedes, “We haven’t yet seen the power for NFTs in cannabis.”

Crypto-Hesitancy

As with anything new, despite mainstream companies embracing NFTs and using them within their marketing and brand recognition strategies, there are skeptics of tokens. The primary argument against the use is that the market is new so assessing value is difficult. It is possible for owners to wind up with something down the road of little or no value. That would not be a positive for customer relations.

Verifying COAs With NFTs

ACS Laboratory is a large marijuana and hemp test lab in Boca Raton, Florida. In November, the lab launched a certificate of analysis (COA) on a cannabis strain as an NFT during the Art Basel Miami Beach annual fair.

A COA includes all details of a product or artwork to help verify its origin. Within the context of cannabis products, an NFT of the COA can prove ownership and verify chemical makeup.

ACS created the NFT by partnering with Blockticity, which describes itself as a “leader in guaranteed certificates of authenticity for the most valuable of possessions.” With this, last December, the first-ever COA for marijuana was encrypted forever on the blockchain as an NFT for a COA. “The blockchain is the future for cannabis and hemp to secure the integrity of the analytical results and the COA, determine permissions and eventually to include payments,” said Roger Brown, president of ACS Laboratories.

Brown said he first thought, “Who is going to buy a digital picture?” He said he later understood that the NFT could help authenticate his companies authentification. ACS now gets calls regularly with questions about the validity of test results.

How it Works

 Using recent innovations, a business or individual can scan a QR code that brings up an NFT of the COA they are interested in. There they have the ability to understand everything about the product. ACS doesn’t think of NFT creation as a revenue stream. The NFT serves to improve consumer confidence of one brand over another as consumers or wholesalers make purchasing decisions

There is now a team at ACS whose job it is to get COAs on blockchain via token technology.

Take-Away

Two very young businesses are finding they may be able to help each other. The Cannabis industry which once only benefitted from the blockchain by using digital currency now is seeing the benefits of non-fungible tokens.  The NFTs are being adopted for brand awareness and recognition as sellers’ marketing departments understand the power of building communities. The industry can also benefit from being able to prove authenticity on everything about the products. This is particularly important for some with ingested, smoked, or vaped consumables. Perhaps other consumable products will also begin using blockchain verification.

Suggested Reading



The Cannabis Path to Legalization and its Implications for Psychedelics

Clarence Thomas’ Statement on Half-in, Half-out Marijuana Laws





NFTs are Being Used to Unlock Revenue in Old Industries

NFTs Explained, What They Are, Why the Excitement

 

Sources

https://mjbizdaily.com/are-nfts-a-scam-or-a-smart-play-for-marijuana-companies/?utm_medium=email&utm_source=newsletter&utm_campaign=MJD_20220202_NEWS_Daily

https://artbasel.com/stories/art-market-report-2021

https://www.marketingdive.com/news/under-armours-wearable-nfts-honor-steph-curry-shattering-3-point-record/616472/

https://www.voguebusiness.com/technology/adidas-reveals-new-nft-project-with-bored-ape-yacht-club

https://www.entrepreneur.com/article/415203

https://www.theverge.com/22833369/nike-rtfkt-nft-sneaker-shoe-metaverse-company

https://www.cnbc.com/2022/01/12/kim-kardashian-and-floyd-mayweather-sued-over-alleged-crypto-scam.html

https://app.poap.xyz/r/token/2227842

https://www.tappancollective.com/pages/about-our-nft-coa

https://www.prnewswire.com/news-releases/acs-laboratory-launches-first-national-hemp-client-coa-nft-301433872.html

https://www.forbes.com/sites/chrisroberts/2021/03/01/would-you-buy-digital-marijuana-blockchain-based-nfts-arrive-in-cannabis/?sh=73b4ed030a3e

 

Stay up to date. Follow us:

 

Release – Voyager Digital Schedules FYQ2 2022 Results and Business Update Conference Call

Posted on by Admin

 


Voyager Digital Schedules FYQ2 2022 Results and Business Update Conference Call

Research, News, and Market Data on Voyager Digital

 

Conference call scheduled for February 15 at 8:00 a.m. ET

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2), one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced that it will host a live webcast and conference call at 8:00 a.m. Eastern Time on Tuesday, February 15 to discuss financial results for the fiscal second quarter 2022 ended December 31, 2021.
 
To access the webcast, please register by clicking here. A live webcast and a replay will be available on the Investor Relations section of the Company’s website at investvoyager.com/investorrelations/events.
 
About Voyager Digital Ltd.
Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 75 different cryptocurrency assets using its easy-to-use mobile application and earn rewards up to 12% annually on more than 35 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides cryptocurrency payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.
 
The TSX has not approved or disapproved of the information contained herein.
 
SOURCE Voyager Digital, Ltd.

Press Contacts
 
Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

Release – Fenixoro Intersects 15 g t Gold 300m Below Previous Deepest Intersection

Posted on by Admin



Fenixoro Intersects 15 g/t Gold 300m Below Previous Deepest Intersection, Increases Known Vertical Range of Mineralization to Over 1500m, Still Open at Depth

Research, News, and Market Data on FenixOro Gold

 

TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — FenixOro Gold Corp (CSE:FENX, OTCQB:FDVXF, Frankfurt:8FD) is pleased to announce additional drill results including the deepest intersection of ore grade gold to date in the Abriaqui district.

  • Hole P014 was drilled to a depth of 1008 meters and intersected 15.71 g/t Gold on the Orquidea vein at an elevation of 1245 meters. This intersection is 300 meters deeper than any previously known mineralization in the Abriaqui district. Mineralization remains open at depth on all veins intersected to date
  • This depth will significantly impact the resource potential modeling on all veins (see Press Releases March 29 and September 28, 2021)
  • The minimum proven vertical range of mineralization on the Orquidea vein is now 1000 meters and the new intersection extends the total vertical range of high grade gold in the greater Abriaqui system of veins to 1500 meters
  • An intersection of 3.6m @ 7.26 g/t gold in P014 correlates with the Baul vein and the previously reported 7.7m @ 8.46 g/t in P006 (Press Release February 24, 2021). This correlation makes Baul the next formally modeled vein, significantly increasing tonnage estimates in the northern drill area.

Fenixoro VP Exploration Stuart Moller commented on exploration results to date. “The 8000 meters of the first two phases of drilling have given us everything we could have anticipated: multiple mineralized veins with good gold grades, thicker zones of up to 20 meters with potential for eventual low cost bulk underground mining, a much greater than expected vertical extent of mineralization, and multiple new high quality drill targets in the southeast license and elsewhere. It’s hard to overstate the importance of the deep hit on Orquidea as it puts an additional 300 vertical meters in play for all the veins in the district and the system is still open at depth.”

Phase 2 drilling has ended with a total of 8062 meters in 16 holes, all in the northwestern licenses of the Abriaqui property (Figure 1). Hole P013 tested the southern extension of the Northwest Vein corridor (NWC). It intersected the Cascada and Santa Teresa veins north of the Cascada Fault but the intersections south of the fault are not yet correlated. Significant results are shown in Table 1.

P014 was designed as a deep test of the potential of the veins on the NWC. It was drilled to a depth of 1008 meters at an angle of -65 degrees from the horizontal. As with most deep holes, drilling was slow and difficult but most objectives were accomplished. The Santa Teresa and Orquidea veins were intersected but it appears that the hole ended just short of Romperopa 1. The deepest intersection of high grade gold, 0.55m @ 15.71 g/t on the Orquidea vein, was at an elevation of 1240 meters. This is the deepest hit to date in the Abriaqui district and it adds 300 meters to the known vertical interval of mineralization. The mineralogy and metal ratios are similar to those higher up in the same vein system indicating that there is no reason to believe that we are nearing the economic bottom of the system.

The minimum vertical interval of potentially economic mineralization in the Orquidea vein is 1000 meters and, including samples taken from mines at higher altitude in the southeastern license, the vertical interval property-wide is 1500 meters. Figure 2 is a longitudinal section of the Orquidea vein showing the drill intersections to date along with sample data from near surface mines. The five drill intersections average 1.79 meters at 11.57 g/t gold. The mineralization is open laterally in both directions and at depth. Importantly, we now know that the geologic system at Abriaqui is capable of generating high gold grades to this depth and that all veins in the district should have similar depth potential.

New Vein For Resource Model
A 3.6 meter intersection with 7.26 g/t gold in the upper part of P014 correlates with the best intersection of the first drill phase, 7.7m @ 8.46 g/t in P006 and a thinner hit in hole P005 on the Baul vein. The vein, which is open to the northwest and at depth, will be the next formally modeled structure to be included in an eventual resource model.

Holes P015 and P016 were drilled from the same platform as infill holes on the NWC and the East-West trending corridor of veins respectively. Assays are awaited for both holes.

Figure 1. Drilling through January, 2022 in the main northwest vein zone. Gold assays in drill holes projected vertically to the surface. Orquidea and Baul Veins shown in blue

Table 1. Recent drill results from holes P013 – P015

Figure 2. Vertical longitudinal section of the Orquidea vein looking northeast showing resource potential block expanded at depth by 300 meters by the intersection in P014. The five drill intercepts average 1.79m @ 11.55 g/t gold.

About FenixOro Gold Corp.
FenixOro Gold Corp is a Canadian company focused on acquiring and exploring gold projects with world class exploration potential in the most prolific gold producing regions of Colombia. FenixOro’s flagship property, the Abriaqui project, is the closest project to Continental Gold’s Buritica project. It is located 15 km to the west in Antioquia State at the northern end of the Mid-Cauca gold belt, a geological trend which has seen multiple large gold discoveries in the past 10 years including Buritica and Anglo Gold’s Nuevo Chaquiro and La Colosa. As documented in “NI 43-101 Technical Report on the Abriaqui project Antioquia State, Colombia” (December 5, 2019), the geological characteristics of Abriaqui and Buritica are similar. Since the preparation of this report a Phase 1 drilling program has been completed at Abriaqui resulting in a significant discovery of a high grade, “Buritica style” gold deposit. A Phase 2 drilling program has recently commenced.

FenixOro’s VP of Exploration, Stuart Moller, led the discovery team at Buritica for Continental Gold in 2007-2011. At the time of its latest public report, the Buritica Mine contains measured plus indicated resources of 5.32 million ounces of gold (16.02 Mt grading 10.32 g/t) plus a 6.02 million ounce inferred resource (21.87 Mt grading 8.56 g/t) for a total of 11.34 million ounces of gold resources Buritica began formal production in November 2020 and has expected annual average production of 250,000 ounces at an all-in sustaining cost of approximately US$600 per ounce. Resources, cost and production data are taken from Continental Gold’s “NI 43-101 Buritica Mineral Resource 2019-01, Antioquia, Colombia” (18 March, 2019). Continental Gold was recently the subject of a takeover by Zijin Mining in an all-cash transaction valued at C$1.4 billion.

Technical Information
Stuart Moller, Vice President Exploration and Director of the Company and a Qualified Person for the purposes of NI 43-101 (P.Geo, British Colombia), has prepared or supervised the preparation of the technical information contained in this press release. Mr. Moller has more than 40 years of experience in exploration for precious and other metals including ten in Colombia and is a Fellow of the Society of Economic Geologists.

Drill core sampling is done in accordance with industry standards. The HQ and NQ diameter core is sawed, and half core samples are submitted to the laboratory. The other half core alongwith laboratory coarse reject material and sample pulps are stored in secure facilities on site and/or in the sample prep lab. Following strict chain of custody protocols, the samples are driven to the ISO 17025:2017 certified ALS Laboratory sample preparation facility in Medellin and ALS ships the prepared pulps to their assay laboratory in Lima, Peru. As of November, 2021 similar procedures have been utilized by the ISO 9001:2015 certified Medellin branch of Ontario-based Actlabs. Blanks, duplicates, and certified reference standards totaling 15% of the total samples are inserted into the sample stream. To date, no material quality control issues have been detected. Gold is analyzed by fire assay with 50 gram charges for grades in excess of 10 grams per tonne and the additional elements are analyzed by ICP with appropriate followup for over- limits.

Reported grade intervals are calculated using uncut gold values. Maximum sample length is one meter. Intervals which include multiple samples are calculated using the full geologic interval of mineralization at a 1 g/t gold external cutoff grade and are not subject to specific rules for cutoff grades within the zones. As such, quoted thickness and grade of these intervals do not necessarily represent optimized economic intervals in a potential future mine. Reported sample and interval widths in drill holes are based on lengths of individual samples in core and do not necessarily represent true widths of mineralization. True widths will sometimes be less than the quoted interval lengths. Intervals defined by channel samples represent true widths of mineralization in vertical veins.

There are currently no NI 43-101 compliant resources or reserves in the project area. The analysis of drill and channel results is intended to estimate the potential for future resources which will require significant additional drilling to define.

Forward Looking Information
This news release contains certain forward-looking information. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Specifically, this news release contains forward looking information regarding the potential economic significance of drill results at the Abriaqui Project, conclusions as to resource potential derived from that data set, and implied assumptions as to the potential future economic viability of the gold grades and vein thicknesses reported. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Although FenixOro has no reason to believe otherwise, there can be no assurance that the planned drill program will be completed as uncertainties exist related to future project financing and future environmental permitting. Although FenixOro has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be additional factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information.

FenixOro Gold Corp
John Carlesso, CEO
Email: info@FenixOro.com
Website: www.FenixOro.com
Telephone: 1-833-ORO-GOLD

Flotek Industries (FTK) – Partnership provides growth adds an investment partner and improves the financial position

Posted on by Admin

Thursday, February 03, 2022

Flotek Industries (FTK)
Partnership provides growth, adds an investment partner, and improves the financial position

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. Flotek Industries, Inc. is a technology-driven, specialty chemistry and data company that helps customers across industrial, commercial and consumer markets improve their Environmental, Social and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its real-time data platforms and green chemistry technologies. Flotek serves downstream, midstream and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit Flotek’s web site at www.flotekind.com.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Flotek and ProFrac enter into a three-year agreement to integrate operations. ProFrac, the largest private provider of hydraulic fracturing services, commits to use Flotek chemistry solutions in part of its operations in exchange for $10 million in convertible notes. ProFrac will also participate in a PIPE sale of notes. See Flotek press release for details.

    The agreement provides growth and stability — view it as a sales agreement.  The agreement creates a backlog of $230 million and should more than double sales, while providing stability. We believe the agreement could ultimately be extended and lead to others …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

PsyBio Therapeutics to Participate in Citi’s Psychedelic Drug Video Call Series

Posted on by Admin


PsyBio Therapeutics to Participate in Citi’s Psychedelic Drug Video Call Series

Research, News, and Market Data on PsyBio

 

 OXFORD, Ohio and COCONUT CREEK, Fla., Feb. 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, Chairman and Chief Executive Officer of the Company, will participate in Citi’s Psychedelic Drug Video Call Series.

Hosted by Neena Bitritto-Garg, Vice President Research Analyst, Biotech, the fireside chat with PsyBio will take place on Thursday, February 3, 2022 at 10:00am Eastern Time.

To register for the event, please contact your appropriate Citi representative directly.

To schedule a meeting with the PsyBio management team, please contact KCSA Strategic Communications by emailing PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The U.S. Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA- approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Release – Flotek and Profac Team Up to Provide Sustainable Vertically Integrated Solutions

Posted on by Admin


Flotek and Profac Team Up to Provide Sustainable, Vertically Integrated Solutions

Research, News, and Market Data on Flotek Industries

 

Innovative Multi-Year Partnership Creates Compelling Offering to Improve Operators’ ESG and Operational Performance

HOUSTON AND WILLOW PARK, TX – February 2, 2022 – Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK), a leader in technology-driven, specialty green chemistry solutions, announced today it has entered into a long-term agreement with ProFrac Services, LLC (“ProFrac”), the largest private North American provider of hydraulic fracturing services, to provide its full portfolio of sustainable chemistry solutions to a dedicated portion of ProFrac’s hydraulic fracturing fleets.

The partnership creates a compelling, vertically integrated solution to enable E&Ps to more sustainably develop natural resources, while reducing the total cost of ownership. The agreement leverages ProFrac’s leading market position and new technologies that significantly reduce greenhouse gas (“GHG”) emissions and increase efficiency with Flotek’s green chemistries that reduce the environmental impact of energy by increasing customers’ operational and ESG performance beyond existing sustainability practices.

Under the terms of the contract, Flotek will provide full downhole chemistry solutions for a required minimum number of fleets for three years. This creates an immediate expected contracted backlog of revenue greater than $230 million, based on estimated chemical volumes and pricing, and is anticipated to represent annual recurring revenue in contrast to traditionally transactional purchases.

Key Contractual Highlights:

  • Scope: Full downhole chemistry for the greater of 33% of ProFrac’s crews or 10 crews as a minimum
  • Duration: Three years
  • Protections: Flotek will receive 25% of the difference between the committed volumes and the shortfall should the defined scope not be achieved

In exchange for entry into the multi-year revenue commitment, ProFrac will receive $10 million initial principal amount of notes that are convertible into Flotek common stock (as described below). In addition, ProFrac will be permitted to designate up to two new directors to Flotek’s board of directors. Simultaneously, Flotek entered into a Private Investment in Public Equity (PIPE) transaction with a consortium of investors to secure growth capital for the Company. Pursuant to the PIPE transaction, Flotek will issue $21.2 million aggregate initial principal amount of convertible notes for net cash proceeds of approximately $19 million. The investors are ProFrac Holdings, LLC, Burlington Ventures Ltd., entities associated with North Sound Management, certain funds associated with one of Flotek’s directors including the D3 Family Fund and the D3 Bulldog Fund, and Firestorm Capital LLC. The notes issued to ProFrac and in the PIPE transaction accrue paid-in-kind interest at a rate of 10% per annum, have a maturity of one year, and are converted into common stock of Flotek (a) at the holder’s option at any time prior to maturity, at a price of $1.088125 per share, (b) at Flotek’s option, if the volume-weighted average trading price of Flotek’s common stock equals or exceeds $2.50 for 20 trading days during a 30 consecutive trading day period, or (c) at maturity, at a price of $0.8705.

John W. Gibson, Jr., Chairman, President, and Chief Executive Officer of Flotek stated: “We are excited to establish this long-term strategic partnership with ProFrac. We believe the relationship creates a compelling ESG solution for the industry and delivers long-term mutual benefit for both companies’ customers. Together, we have the opportunity to reduce emissions and establish green chemistry solutions, thereby protecting air, land and water. This transformative agreement creates a comprehensive completions solution merging operational efficiency congruent with ESG objectives.”

Matt Wilks, President and CFO of ProFrac stated: “Flotek is a great company that we’re privileged to work with. We believe this transaction presents a unique opportunity to create mutual value as we each expand.” Ryan Ezell, Ph.D, President of Flotek’s Chemistry Technologies segment, said: “Our innovative partnership with ProFrac will deliver differentiated performance for operators, while reducing the total cost of ownership and environmental risk. We are honored to collaborate with an established industry leader, furthering our strategy to rebuild our indirect channels to market with service companies, significantly accelerating our revenue growth and the industries adoption of ESG principles.” Piper Sandler is serving as the exclusive financial advisor to Flotek.

About Flotek Industries, Inc.

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology-driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment provides sustainable, optimized chemistry solutions that maximize our customer’s value by elevating their ESG performance, lowering operational costs, and delivering improved return on invested capital. The Company’s proprietary green chemistries, specialty chemistries, logistics, and technology services enable its customers to pursue improved efficiencies and performance throughout the life cycle of its desired chemical applications program. Major integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, geothermal energy companies, solar energy companies and advanced alternative energy companies benefit from best-in-class technology, field operations, and continuous improvement exercises that go beyond existing sustainability practices. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

About ProFrac Holding Corp

ProFrac is a growth-oriented, vertically integrated and innovation-driven energy services company providing hydraulic fracturing, completion services and other complementary products and services to leading upstream oil and gas companies engaged in the exploration and production (“E&P”) of North American unconventional oil and natural gas resources. Founded in 2016, ProFrac was built to be the go-to service provider for E&P companies’ most demanding hydraulic fracturing needs. ProFrac is focused on employing new technologies to significantly reduce “greenhouse gas” (“GHG”) emissions and increase efficiency in what has historically been an emissions-intensive component of the unconventional E&P development process. For more information, please visit https://profrac.com/.

Forward-Looking Statements

Certain statements set forth in this press release constitute forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of tile Securities Exchange Act of 1934) regarding Flotek Industries, Inc.’s business, financial condition, results of operations and prospects. Words such as will, continue, expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this press release. Although forward-looking statements in this press release reflect the good faith judgment of management. such statements can only be based on facts and factors currently known to management. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact the company are set forth in the Company’s most recent filing with the Securities and Exchange Commission on Form 10-K (including, without limitation, in the “Risk Factors” section thereof), and in the Company’s other SEC filings and publicly available documents. Readers are urged not to place undue reliance on these forward -looking statements, which speak only as of the dale of this press release. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect, any event or circumstance that may arise after the date of this press release.

###

Inquiries, contact:

Investor Relations

E: ir@flotekind.com

P: (713) 726-5322

Release – PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial

Posted on by Admin



PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

Research, News, and Market Data on PDS Biotech

 

Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor naïve cohort

FLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective response benchmarks. The trial, which studies PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), will now progress to full enrollment of 54 patients in this group of checkpoint inhibitor (CPI) naïve patients. As pre-specified in the clinical trial design, the achievement of an objective response as measured by radiographic tumor responses according to RECIST 1.1 (tumor reduction of 30% or more) confirmed by two separate measurements among at least four or more of the first 17 patients in the CPI naïve arm allows that arm to progress to full enrollment. We anticipate these data will be presented in more detail at an upcoming medical conference.  

VERSATILE-002, being conducted in collaboration with Merck (known as MSD outside the US and Canada), is being studied in two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread. The first group have not been previously treated with a checkpoint inhibitor (CPI naïve). An initial assessment of the combination in a second group of 21 patients who have failed prior therapy with checkpoint inhibitors (CPI refractory) is ongoing.   

“The achievement of this important milestone in the VERSATILE-002 Phase 2 clinical trial strengthens the evidence of our novel Versamune® platform’s potential ability to induce high levels of tumor-specific CD8+ killer T-cells that attack the cancer to achieve tumor regression,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “The initial data solidifies our belief that PDS0101’s demonstrated preclinical efficacy when combined with KEYTRUDA® has the potential to significantly improve clinical outcomes for patients with advanced HPV16-positive head and neck cancers.”

Dr. Jared Weiss, Section Chief of Thoracic and Head and Neck Oncology at the University of Carolina at Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center, is serving as the Lead Principal Investigator of VERSATILE-002. Patients interested in enrolling in this clinical study should email info@pdsbiotech.com or visit the website at http://pdsbiotech.com/VERSATILE-002 to learn more.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms.

Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.  The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.  

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital

Release – PsyBio Therapeutics to Participate in Citis Psychedelic Drug Video Call Series

Posted on by Admin


PsyBio Therapeutics to Participate in Citi’s Psychedelic Drug Video Call Series

Research, News, and Market Data on PsyBio

 

 OXFORD, Ohio and COCONUT CREEK, Fla., Feb. 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, Chairman and Chief Executive Officer of the Company, will participate in Citi’s Psychedelic Drug Video Call Series.

Hosted by Neena Bitritto-Garg, Vice President Research Analyst, Biotech, the fireside chat with PsyBio will take place on Thursday, February 3, 2022 at 10:00am Eastern Time.

To register for the event, please contact your appropriate Citi representative directly.

To schedule a meeting with the PsyBio management team, please contact KCSA Strategic Communications by emailing PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The U.S. Food and Drug Administration (“FDA“) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA- approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (“TSXV“) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

Flotek and Profac Team Up to Provide Sustainable, Vertically Integrated Solutions

Posted on by Admin


Flotek and Profac Team Up to Provide Sustainable, Vertically Integrated Solutions

Research, News, and Market Data on Flotek Industries

 

Innovative Multi-Year Partnership Creates Compelling Offering to Improve Operators’ ESG and Operational Performance

HOUSTON AND WILLOW PARK, TX – February 2, 2022 – Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK), a leader in technology-driven, specialty green chemistry solutions, announced today it has entered into a long-term agreement with ProFrac Services, LLC (“ProFrac”), the largest private North American provider of hydraulic fracturing services, to provide its full portfolio of sustainable chemistry solutions to a dedicated portion of ProFrac’s hydraulic fracturing fleets.

The partnership creates a compelling, vertically integrated solution to enable E&Ps to more sustainably develop natural resources, while reducing the total cost of ownership. The agreement leverages ProFrac’s leading market position and new technologies that significantly reduce greenhouse gas (“GHG”) emissions and increase efficiency with Flotek’s green chemistries that reduce the environmental impact of energy by increasing customers’ operational and ESG performance beyond existing sustainability practices.

Under the terms of the contract, Flotek will provide full downhole chemistry solutions for a required minimum number of fleets for three years. This creates an immediate expected contracted backlog of revenue greater than $230 million, based on estimated chemical volumes and pricing, and is anticipated to represent annual recurring revenue in contrast to traditionally transactional purchases.

Key Contractual Highlights:

  • Scope: Full downhole chemistry for the greater of 33% of ProFrac’s crews or 10 crews as a minimum
  • Duration: Three years
  • Protections: Flotek will receive 25% of the difference between the committed volumes and the shortfall should the defined scope not be achieved

In exchange for entry into the multi-year revenue commitment, ProFrac will receive $10 million initial principal amount of notes that are convertible into Flotek common stock (as described below). In addition, ProFrac will be permitted to designate up to two new directors to Flotek’s board of directors. Simultaneously, Flotek entered into a Private Investment in Public Equity (PIPE) transaction with a consortium of investors to secure growth capital for the Company. Pursuant to the PIPE transaction, Flotek will issue $21.2 million aggregate initial principal amount of convertible notes for net cash proceeds of approximately $19 million. The investors are ProFrac Holdings, LLC, Burlington Ventures Ltd., entities associated with North Sound Management, certain funds associated with one of Flotek’s directors including the D3 Family Fund and the D3 Bulldog Fund, and Firestorm Capital LLC. The notes issued to ProFrac and in the PIPE transaction accrue paid-in-kind interest at a rate of 10% per annum, have a maturity of one year, and are converted into common stock of Flotek (a) at the holder’s option at any time prior to maturity, at a price of $1.088125 per share, (b) at Flotek’s option, if the volume-weighted average trading price of Flotek’s common stock equals or exceeds $2.50 for 20 trading days during a 30 consecutive trading day period, or (c) at maturity, at a price of $0.8705.

John W. Gibson, Jr., Chairman, President, and Chief Executive Officer of Flotek stated: “We are excited to establish this long-term strategic partnership with ProFrac. We believe the relationship creates a compelling ESG solution for the industry and delivers long-term mutual benefit for both companies’ customers. Together, we have the opportunity to reduce emissions and establish green chemistry solutions, thereby protecting air, land and water. This transformative agreement creates a comprehensive completions solution merging operational efficiency congruent with ESG objectives.”

Matt Wilks, President and CFO of ProFrac stated: “Flotek is a great company that we’re privileged to work with. We believe this transaction presents a unique opportunity to create mutual value as we each expand.” Ryan Ezell, Ph.D, President of Flotek’s Chemistry Technologies segment, said: “Our innovative partnership with ProFrac will deliver differentiated performance for operators, while reducing the total cost of ownership and environmental risk. We are honored to collaborate with an established industry leader, furthering our strategy to rebuild our indirect channels to market with service companies, significantly accelerating our revenue growth and the industries adoption of ESG principles.” Piper Sandler is serving as the exclusive financial advisor to Flotek.

About Flotek Industries, Inc.

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology-driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment provides sustainable, optimized chemistry solutions that maximize our customer’s value by elevating their ESG performance, lowering operational costs, and delivering improved return on invested capital. The Company’s proprietary green chemistries, specialty chemistries, logistics, and technology services enable its customers to pursue improved efficiencies and performance throughout the life cycle of its desired chemical applications program. Major integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, geothermal energy companies, solar energy companies and advanced alternative energy companies benefit from best-in-class technology, field operations, and continuous improvement exercises that go beyond existing sustainability practices. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

About ProFrac Holding Corp

ProFrac is a growth-oriented, vertically integrated and innovation-driven energy services company providing hydraulic fracturing, completion services and other complementary products and services to leading upstream oil and gas companies engaged in the exploration and production (“E&P”) of North American unconventional oil and natural gas resources. Founded in 2016, ProFrac was built to be the go-to service provider for E&P companies’ most demanding hydraulic fracturing needs. ProFrac is focused on employing new technologies to significantly reduce “greenhouse gas” (“GHG”) emissions and increase efficiency in what has historically been an emissions-intensive component of the unconventional E&P development process. For more information, please visit https://profrac.com/.

Forward-Looking Statements

Certain statements set forth in this press release constitute forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of tile Securities Exchange Act of 1934) regarding Flotek Industries, Inc.’s business, financial condition, results of operations and prospects. Words such as will, continue, expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this press release. Although forward-looking statements in this press release reflect the good faith judgment of management. such statements can only be based on facts and factors currently known to management. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact the company are set forth in the Company’s most recent filing with the Securities and Exchange Commission on Form 10-K (including, without limitation, in the “Risk Factors” section thereof), and in the Company’s other SEC filings and publicly available documents. Readers are urged not to place undue reliance on these forward -looking statements, which speak only as of the dale of this press release. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect, any event or circumstance that may arise after the date of this press release.

###

Inquiries, contact:

Investor Relations

E: ir@flotekind.com

P: (713) 726-5322

Euroseas (ESEA) – Expanding New Build Program But Still Expect Dividend and or Buy Backs

Posted on by Admin

Wednesday, February 02, 2022

Euroseas (ESEA)
Expanding New Build Program But Still Expect Dividend and/or Buy Backs

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two new build feeders added to existing new build program. Two Eco design 2,800 TEU Feeders will be built at Hyundai Mipo in South Korea at an estimated cost of ~$85 million, or ~12% above the Feeders ordered in 2Q2021. Deliveries are slated for 4Q2023/1Q2024. The new build program expands to four Feeders, and we view this move as a sign of confidence in the Feeder market outlook in part due to an order book that is below the order book for intermediate and larger containerships.

    First two Feeder new builds on track and time charter interest developing.  The first two Eco design 2,800 TEU Feeders ordered in 2Q2021 are on track, with deliveries are slated for 1Q2023/2Q2023. Total estimated cost is ~$76 million. On the last call, management indicated that interest was picking up and time charters are likely to be in place prior to delivery …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Posted on by Admin



Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Research, News, and Market Data on Neovasc

 

VANCOUVER and MINNEAPOLIS – ( NewMediaWire> ) – February 02, 2022 –  Neovasc Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York. The consolidated amended complaint was dismissed in its entirety with prejudice and without leave to amend.

“From the beginning, we committed to vigorously defend against these allegations,” said Fred Colen, Chief Executive Officer of Neovasc. “We could not be more pleased with the Courts decision to completely dismiss this action with prejudice, which is a clear rejection of the claims advanced in this litigation. We intend to continue to focus on our important mission of creating better outcomes for difficult-to-treat cardiology patients as we move forward.”

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com .

Contacts

Investors:
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media:

Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, market and other conditions as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2021 (copies of which may be obtained at www.sedar.com or www.sec.gov ). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.